Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer ( SITC ) 2024 Annual Meeting
Data further confirms Company's "Pulse-Prime" hypothesis Data further confirms Company's "Pulse-Prime" hypothesis ...
| Ticker |
Sentiment |
Impact |
|
BGNE
|
Neutral
|
6 %
|
|
INDP
|
Neutral
|
8 %
|
